In recent years, medications originally developed to treat Type 2 diabetes, obesity, and other weight-related conditions—such as semaglutide and liraglutide—are showing promise in treating substance use disorders (SUDs). These medications belong to a class of glucagon-like peptide-1 (GLP-1) receptor agonists and are marketed under brand names such as Ozempic®, Wegovy®, Victoza®, and Saxenda®.  GLP-1 is a naturally occurring hormone produced in the gut and brain that regulates

In recent years, medications originally developed to treat Type 2 diabetes, obesity, and other weight-related conditions—such as semaglutide and liraglutide—are showing promise in treating substance use disorders (SUDs). These medications belong to a class of glucagon-like peptide-1 (GLP-1) receptor agonists and are marketed under brand names such as Ozempic®, Wegovy®, Victoza®, and Saxenda®.  GLP-1 is a naturally occurring hormone produced in the gut and brain that regulates

According to the latest Monitoring the Future (MTF) Panel Study from the University of Michigan, young and midlife adults are reporting sharp increases in several emerging substance use behaviors, including nicotine pouches, cannabis, vaping, and psychedelics.  For 50 years, MTF surveys nationally representative samples of 8th, 10th, and 12th-graders, tracking trends in youth substance use and following a subset of 12th-grade participants into adulthood. Today, the MTF Panel

The Responding to Addiction Participant Manual—the official companion to our instructor-led Responding to Addiction training—is now available for purchase on Amazon. This accessible guide reinforces and expands on training content with science-backed information about substance use disorders, including: How addiction impacts the brain Recognizing signs and symptoms Evidence-based treatment approaches, including medication for addiction treatment Practical guidance on how to

There have been national policy changes related to the use of cannabis for medical purposes, yet there are many questions from the public and healthcare providers about medical use. The FDA has approved specific cannabis-derived and cannabis-related therapeutics for treating certain medical conditions, but it has not approved cannabis itself for treating any health conditions. This webinar examines the scientific evidence on cannabis and health, while separating evidence-base

You’re invited to a special Reception on Capitol Hill hosted by the Addiction Policy Forum, celebrating 10 years of service.